tiprankstipranks
AddLife AB Class B (GB:0REZ)
LSE:0REZ
UK Market
0REZ
AddLife AB
RESEARCH TOOLSreports

AddLife AB (0REZ) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0REZ Analyst Ratings

Hold
1Ratings
Hold
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
AddLife
AB
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0REZ Stock 12 Month Forecast

Average Price Target

kr180.00
▲(11.77% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for AddLife AB in the last 3 months. The average price target is kr180.00 with a high forecast of kr180.00 and a low forecast of kr180.00. The average price target represents a 11.77% change from the last price of kr161.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"134":"kr134","203":"kr203","151.25":"kr151.3","168.5":"kr168.5","185.75":"kr185.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr180.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[134,151.25,168.5,185.75,203],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,161.697,163.1049230769231,164.51284615384617,165.92076923076922,167.3286923076923,168.7366153846154,170.14453846153847,171.55246153846153,172.9603846153846,174.3683076923077,175.77623076923078,177.18415384615383,178.59207692307692,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,161.697,163.1049230769231,164.51284615384617,165.92076923076922,167.3286923076923,168.7366153846154,170.14453846153847,171.55246153846153,172.9603846153846,174.3683076923077,175.77623076923078,177.18415384615383,178.59207692307692,{"y":180,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,161.697,163.1049230769231,164.51284615384617,165.92076923076922,167.3286923076923,168.7366153846154,170.14453846153847,171.55246153846153,172.9603846153846,174.3683076923077,175.77623076923078,177.18415384615383,178.59207692307692,{"y":180,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":168.048,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":177.377,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":175.426,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":202.882,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":186.097,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":156.021,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":135.362,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":148.107,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":142.774,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.577,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.498,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.469,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":161.697,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr180.00Average Price Targetkr180.00Lowest Price Targetkr180.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
SEB Enskilda Analyst forecast on GB:0REZ
Jakob Lembke
SEB Enskilda
Not Ranked
SEB Enskilda
kr180
Hold
11.77%
Upside
Downgraded
06/29/26
AddLife downgraded to Hold from Buy at SEB EquitiesAddLife downgraded to Hold from Buy at SEB Equities
UBS Analyst forecast on GB:0REZ
Unknown Analyst
UBS
Not Ranked
UBS
kr165
Buy
2.45%
Upside
Upgraded
04/28/26
AddLife upgraded to Buy from Neutral at UBSAddLife upgraded to Buy from Neutral at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
SEB Enskilda Analyst forecast on GB:0REZ
Jakob Lembke
SEB Enskilda
Not Ranked
SEB Enskilda
kr180
Hold
11.77%
Upside
Downgraded
06/29/26
AddLife downgraded to Hold from Buy at SEB EquitiesAddLife downgraded to Hold from Buy at SEB Equities
UBS Analyst forecast on GB:0REZ
Unknown Analyst
UBS
Not Ranked
UBS
kr165
Buy
2.45%
Upside
Upgraded
04/28/26
AddLife upgraded to Buy from Neutral at UBSAddLife upgraded to Buy from Neutral at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AddLife AB

3 Months
OpenAI Medical - Instruments and SuppliesTipRanks - OpenAI
Success Rate
0/2 ratings generated profit
0%
Average Return
-2.55%
Copying OpenAI Medical - Instruments and Supplies's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -2.55% per trade.
1 Year
OpenAI Medical - Instruments and SuppliesTipRanks - OpenAI
Success Rate
0/2 ratings generated profit
0%
Average Return
-10.45%
Copying OpenAI Medical - Instruments and Supplies's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -10.45% per trade.
2 Years
OpenAI Medical - Instruments and SuppliesTipRanks - OpenAI
Success Rate
0/2 ratings generated profit
0%
Average Return
-10.45%
Copying OpenAI Medical - Instruments and Supplies's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -10.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0REZ Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
1
1
1
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
1
1
0
0
In the current month, 0REZ has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0REZ average Analyst price target in the past 3 months is 180.00.
Each month's total comprises the sum of three months' worth of ratings.

0REZ Financial Forecast

0REZ Earnings Forecast

Next quarter’s earnings estimate for 0REZ is kr0.88 with a range of kr0.78 to kr0.96. The previous quarter’s EPS was kr1.07. 0REZ beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0REZ has Outperformed its overall industry.
Next quarter’s earnings estimate for 0REZ is kr0.88 with a range of kr0.78 to kr0.96. The previous quarter’s EPS was kr1.07. 0REZ beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0REZ has Outperformed its overall industry.

0REZ Sales Forecast

Next quarter’s sales forecast for 0REZ is kr2.56B with a range of kr2.50B to kr2.58B. The previous quarter’s sales results were kr2.72B. 0REZ beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0REZ has Outperformed its overall industry.
Next quarter’s sales forecast for 0REZ is kr2.56B with a range of kr2.50B to kr2.58B. The previous quarter’s sales results were kr2.72B. 0REZ beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0REZ has Outperformed its overall industry.

0REZ Stock Forecast FAQ

What is GB:0REZ’s average 12-month price target, according to analysts?
Based on analyst ratings, AddLife AB Class B’s 12-month average price target is 180.00.
    What is GB:0REZ’s upside potential, based on the analysts’ average price target?
    AddLife AB Class B has 11.77% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AddLife AB Class B a Buy, Sell or Hold?
          AddLife AB Class B has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
            What is AddLife AB Class B’s share price target?
            The average share price target for AddLife AB Class B is 180.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is kr180.00 ,and the lowest forecast is kr180.00. The average share price target represents 11.77% Increase from the current price of kr161.05.
              What do analysts say about AddLife AB Class B?
              AddLife AB Class B’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of AddLife AB Class B?
                To buy shares of GB:0REZ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.